Resumen de Hodgkin lymphoma
Hodgkin lymphoma typically presents as a painless mass and can be sub-classified into classical and nodular lymphocyte predominant forms, each of which has characteristic age of incidence peaks. Encouragingly, most patients who develop Hodgkin lymphoma can now be cured. In view of this, therapy adapted to interim positron emission tomography/computed tomography response is under investigation in an attempt to identify: (a) those patients with good risk disease who may benefit from early attenuation of therapy (to limit risks of long-term treatment associated complications) while maintaining treatment efficacy and (b) those patients with poor risk disease who may benefit from early treatment escalation. However, a small proportion of patients may either be refractory to or relapse after first-line therapy. For such cases, highly active novel agents may overcome these issues and allow more patients to be cured. In future, such agents may be used as less toxic initial therapy in cases intolerant of current conventional treatment approaches (particularly those patients who are frail, elderly or who have multiple co-morbidities), while incorporating these agents in to upfront combination regimens may limit the chemotherapy resistance that underpins refractory/relapsed disease.
